Seller record · Telehealth service

Mirabel Meds

By Peptide Alliance, Editorial publisherRecorded October 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S3, pharmacy identification: Home, contact, terms, privacy and both treatment pages refer to partner compounding pharmacies without naming a dispensing pharmacy. 2 more criteria also fail; see the table below.

At a glance

Mirabel MedsTelehealth service

5/8criteria passed

Price: Not printed before a consultation or sign-up
Sells: compounded semaglutide, compounded tirzepatide
FDA letters: None on file

Visit Mirabel Meds See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform offering compounded semaglutide and tirzepatide through independent licensed clinicians. Its public pages do not name the dispensing pharmacy or print a treatment price.

Operating entity Mirabel Meds, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Mirabel Meds' semaglutide product page
S2	Prescription gating	PASS	Mirabel Meds' semaglutide product page
S3	Pharmacy identification	FAIL	Mirabel Meds' terms; Mirabel Meds' semaglutide product page
S4	Compounding disclosure	PASS	Mirabel Meds' website
S5	Analytical documentation	FAIL	Mirabel Meds' semaglutide product page; Mirabel Meds' tirzepatide product page
S6	Business address	PASS	Mirabel Meds' privacy page
S7	Price disclosure	FAIL	Mirabel Meds' terms; Mirabel Meds' semaglutide product page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSTreatment pages describe assessment by a clinician licensed in the patient’s state, with prescriptions decided independently by that clinician.Source: Mirabel Meds' semaglutide product page.

S2PASSThe treatment page says every program begins with consultation and requires provider authorization; the footer says treatment charges are not processed if the patient is not medically approved.Source: Mirabel Meds' semaglutide product page.

S3FAILHome, contact, terms, privacy and both treatment pages refer to partner compounding pharmacies without naming a dispensing pharmacy.Source: Mirabel Meds' terms; Mirabel Meds' semaglutide product page.

S4PASSThe footer distinguishes compounded preparations and explicitly states they are not FDA-approved or independently verified by the FDA for safety, efficacy and quality.Source: Mirabel Meds' website.

S5FAILNo lot-specific certificate or batch testing document is published in the home, contact, terms, privacy or semaglutide and tirzepatide treatment pages examined.Source: Mirabel Meds' semaglutide product page; Mirabel Meds' tirzepatide product page.

S6PASSThe privacy policy gives Mirabel Meds, Inc. a mailing address at 500 S. Australian Ave, Suite 600,1069, West Palm Beach, FL 33401.Source: Mirabel Meds' privacy page.

S7FAILNo treatment price is printed on the home, contact, terms or two treatment pages examined; terms defer prices to the point of purchase.Source: Mirabel Meds' terms; Mirabel Meds' semaglutide product page.

S8PASSNo FDA warning letter names Mirabel or Mirabel Meds, Inc., and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit Mirabel Meds

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.